Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | NPY4R | P50391 | 13/20 | 0.53 |
| ▸ | NPY1R | P25929 | 7/20 | 0.53 |
| ▸ | NPY2R | P49146 | 5/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Laminin SCHEMBL2182800 | 1.00 | OPRD1 (0.55) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL29479578 | 0.94 | OPRM1 (0.53) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL30211355 | 0.93 | NPY4R (0.52) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL29502186 | 0.92 | NPY4R (0.52) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL30405659 | 0.90 | NPY4R (0.53) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL31307267 | 0.90 | OPRM1 (0.56) | OPRD1OPRM1OPRK1KISS1R | |
| SCHEMBL30104120 | 0.89 | OPRM1 (0.45) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL29472190 | 0.89 | OPRD1 (0.54) | OPRD1OPRM1OPRK1KISS1R | |
| SCHEMBL30211356 | 0.88 | NPY4R (0.50) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| Laminin SCHEMBL29354054 | 0.88 | NTSR1 (0.56) | OPRD1OPRM1OPRK1NPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115353546-B | Preparation and application of oligopeptide modified bisindolylethyl-beta-carboline-3-carboxylic acid | 首都医科大学 | 2024-10-08 | — | — | CN | claimed |
| US-20240197960-A1 | VASCULAR REPAIR PATCH | INSTITUT QUIMIC DE SARRIA CETS FUNDACIO PRIVADA (ES) | 2024-06-20 | — | — | US | claimed |
| US-20240199698-A1 | PEPTIDE AMPHIPHILE COMPOSITIONS AND METHODS OF USE THEREOF | Endomimetics LLC | 2024-06-20 | — | — | US | claimed |
| EP-3765102-B1 | VASCULAR REPAIR PATCH | INSTITUT QUIM DE SARRIA CETS FUNDACIO PRIVADA (ES) | 2024-05-15 | — | — | EP | claimed |
| US-11944723-B2 | Vascular repair patch | INSTITUT QUIMIC DE SARRIA CETS FUNDACIO PRIVADA (ES) | 2024-04-02 | — | — | US | claimed |
| US-11788063-B2 | Systems and methods for culturing epithelial cells | THE BROAD INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | claimed |
| US-11718687-B2 | Biomoletron for regulation stem cell differentiation | SOGANGN UNIVERSITY RESEARCH FOUNDATION (KR) | 2023-08-08 | — | — | US | claimed |
| CN-112010937-B | YIGSR modified pentacyclic piperazinedione and preparation and application thereof | 首都医科大学（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-114214280-B | Method for culturing cell spheres by using self-assembled polypeptide derivative hydrogel, cell spheres and application thereof | 南开大学 | 2022-11-29 | — | — | CN | claimed |
| CN-115353546-A | Preparation and application of oligopeptide-modified bis-indolylethyl-beta-carboline-3-carboxylic acid | 首都医科大学 | 2022-11-18 | — | — | CN | claimed |
| CN-107522773-B | Pentapeptide modified rhodamine B compound and preparation method and application thereof | 武汉工程大学 | 2021-06-01 | — | — | CN | claimed |
| CN-107739528-A | A kind of pentapeptide is modified cyanine dye compound and its preparation method and application | 武汉工程大学 | 2018-02-27 | — | — | CN | claimed |
| CN-107522773-A | A kind of pentapeptide is modified rhodamine B compound and its preparation method and application | 武汉工程大学 | 2017-12-29 | — | — | CN | claimed |
| CN-103435684-B | 18f-fluorine mark pentapeptide title complex and synthetic method | WUHAN INSTITUTE OF TECHNOLOGY (CN) | 2015-10-28 | — | — | CN | claimed |
| CN-103435684-A | 18F-fluorine labeling pentapeptide complex and synthetic method thereof | WUHAN INST TECHNOLOGY | 2013-12-11 | — | — | CN | claimed |
| US-12599703-B2 | Hybrid heterogeneous hydrogel, manufacturing method and use as an in-situ non-degradable filler implant | NEUROBIOMAT (FR) | 2026-04-14 | — | — | US | disclosed |
| EP-4722341-A1 | METHOD FOR PRODUCING HEMATOPOIETIC PROGENITOR CELL AND METHOD FOR PRODUCING LEUKOCYTE | Sekisui Chemical Co., Ltd. (JP) | 2026-04-08 | — | — | EP | disclosed |
| CN-1694717-A | Irrigation solution and method for inhibition of tumor cell adhesion, pain and inflammation | OMEROS CORP (US) | 2005-11-09 | — | — | CN | disclosed |
| US-20030195461-A1 | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation | OMEROS CORPORATION | 2003-10-16 | — | — | US | disclosed |
| US-6492332-B1 | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation | OMEROS CORPORATION | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599703-B2 | Hybrid heterogeneous hydrogel, manufacturing method and use as an in-situ non-degradable filler implant | CD44, MYB, HPGDS | OPRD1 983/4885OPRM1 2250/4885OPRK1 3472/4885 |
| US-20240199698-A1 | PEPTIDE AMPHIPHILE COMPOSITIONS AND METHODS OF USE THEREOF | PLD4, NGLY1, VIP | OPRD1 1936/4885OPRM1 2617/4885OPRK1 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.